Overview
AI driven discovery is now a battleground for visibility. The teams that win will not treat AI optimization as a separate initiative or a future phase or even one that sits in the responsibility of individual functions within a pharma company. They will operationalize a single, integrated approach that protects traditional search performance while improving the likelihood of accurate inclusion and citation in generated answers, centered around content and brands.
This isn’t a new channel to bolt onto existing plans. LLMs are reshaping how healthcare providers (HCPs) and patients discover, validate, and act on brand and disease information across every touchpoint. As AI-generated answers increasingly mediate the first, and sometimes only brand interaction, Engine Optimization must be built into the broader multichannel strategy, not treated as an SEO side project.
As if it wasn’t hard enough to reach and engage busy healthcare professionals and patient communities, life sciences companies now face new obstacles as AI assistants, AI overviews, and AI modes continue to strengthen their chokehold on digital discovery. Declining visibility, inaccuracies, and reduced site traffic are negatively impacting organizations, across both commercial and medical teams.
The landscape is fraught with confusion, compounding challenges. Traditional search rankings may be strong with no mention in generated answers, mentions and sentiment can be inconsistent across LLMs, and share of voice and sentiment can change quickly from week to week.
Engine Optimization is one way to address these challenges. By combining the fundamentals of Search Engine Optimization (SEO) with the structure, accessibility, and authority signals that LLMs reward, you can help boost discoverability of your digital content.
Much like the early years of SEO, early gains and insights will be based on trial and error. We hear the same questions repeatedly. Do SEO strategies really impact AI results? What AI-SEO specific strategies are available to help pharma and biotech keep pace, and which should be prioritized?
This case study was developed to help answer these very questions.
Challenge
A few years post launch, our client faced a new competitor and an evolving treatment landscape. At the same time, the brand’s HCP website was also experiencing single digit monthly citations (URL links within generated answers). For example, the average number of monthly citations in Google’s AI overviews for the six months preceding optimization was 2.5.
The immediate and pressing short-term goal was to grow brand visibility in a diversified search landscape by increasing AI mentions.
Ideally, our work would boost mentions and citations, but more importantly, the aim was to help ensure positive sentiment and context. A high volume of mentions means less if LLMs are unable to understand the context for appropriate use. To that end, it was imperative that LLMs understood the nuance of the data, so the brand was positioned accurately across both earlier and later lines of therapy.
Over time, the objective would remain to ensure the brand and the science is the single best (or leading) answer for relevant prompts.
Results
Initial optimizations began delivering momentum almost immediately. The collective of strategies implemented in the first sprint improved brand discoverability significantly, demonstrated by the metrics that matter most in digital discovery: AI mentions and citations, and page one ranking.
Get the full approach and results
"*" indicates required fields